Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Documenti analoghi

• A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)
  di: Papp, KA, et al.
  Pubblicazione: (2015)
• Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
  di: Gooderham, M.J., et al.
  Pubblicazione: (2018)
• The safety of etanercept for the treatment of plaque psoriasis
  di: Papp, Kim A
  Pubblicazione: (2007)
• A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
  di: Gottlieb, AB, et al.
  Pubblicazione: (2012)
• Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO‐INSIGHTFUL study
  di: Hong, C‐H., et al.
  Pubblicazione: (2017)